INOVIO received authorization to conduct phase 3 efficacy trial of COVID-19 DNA vaccine candidate, INO-4800 in Brazil
On Aug. 26, 2021, Inovio Pharma announced that it had received regulatory authorization from Brazil’s ANVISA (Agencia Nacional…
INOVIO and Advaccine receive regulatory allowance for prime-boost clinical trials in China using INO-4800, COVID-19 DNA vaccine candidate
On Aug. 9, 2021, Inovio Pharma announced that it had received regulatory allowance for two clinical trials investigating…
INOVIO dosed first participant in phase 2 trial for its DNA vaccine against MERS, a Coronavirus Disease
On Aug. 4, 2021, Inovio Pharma announced that the company had dosed the first Phase 2 trial subject…
INOVIO expanded partnership with Advaccine to conduct global phase 3 efficacy trial of COVID-19 DNA vaccine candidate
On Jun. 8, 2021, Inovio Pharma announced an expansion of its previously announced partnership with Advaccine Biopharmaceuticals to…
OraSure Technologies receives three EUA’s for its COVID-19 rapid antigen tests for non-prescription use
On Jun. 7, 2021, OraSure Technologies announced that it had received Emergency Use Authorization (EUA) from the FDA…
INOVIO’s Pan-COVID-19 vaccine candidate (INO-4802) induces broad immunity against vviral variants in preclinical studies
On May 12, 2021, Inovio Pharma announced that its next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies…
INOVIO announced positive data from phase 2 clinical trial evaluating INO-4800 COVID-19 DNA vaccine
On May 10, 2021, Inovio Pharma announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded…
INOVIO planned for ex-US global phase 3 trial for INO-4800
On Apr. 23, 2021, Inovio Pharma announced that it was planning for a predominantly ex-U.S. Phase 3 trial…
INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
OraSure Technologies submitted COVID-19 rapid antigen prescription home self-test to FDA for EUA
On Mar. 30, 2021, OraSure Technologies announced that it had submitted an application to the U.S. Food and…
The US Department of Defense identified more troops to help administer COVID-19 vaccine
On Mar. 10, 2021, the U.S. Department of Defense (DOD) announced that it had identified additional personnel authorized…
DNA Genotekﾒs OMNIgeneﾮﾷORAL included in EUA granted to Ambry Genetics for use in COVID-19 RT-PCR saliva test
On Jan. 29, 2021, OraSure Technologies announced its OMNIgeneﾮﾷORAL (OM-505) saliva collection kit, a product of subsidiary DNA…
DNA Genotekﾒs OMNIgeneﾮﾷORAL saliva collection device received Health Canada Authorization for COVID-19 testing
On Jan. 28, 2021, OraSure Technologies announced its OMNIgeneﾮﾷORAL (OME-505) saliva collection device, a product of Ottawa-based subsidiary…
OraSure’s OMNIgene-ORAL saliva collection kit selected by Chronomics for use in UK Government travel COVID-19 testing
On Jan. 26, 2021, OraSure Technologies announced that Chronomics had selected the OMNIgene-ORAL (OME-505) saliva collection device as…
Patients in cancer remission at high risk for severe COVID-19 illness
On Jan. 21, 2021, Penn Medicine reported that patients with inactive cancer and not currently undergoing treatments also…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science News | Therapeutics | Vaccine
Cue’s Molecular, point-of-care COVID-19 tests available under HHS and DoD pilot program
On Jan. 19, 2021, Cue Health announced that its molecular, point-of-care COVID-19 Tests were being distributed to five…
INOVIO and Advaccine announced partnership to commercialize COVID-19 DNA vaccine candidate in China
On Jan. 4, 2021, Inovio Pharmaceuticals and Advaccine Biopharmaceuticals announced that they had entered into a collaboration and…
INOVIO announced publication of phase 1 data from COVID-19 DNA vaccine candidate in The Lancet
On Dec. 24, 2020, Inovio Pharmaceuticals announced publication of peer-reviewed Phase 1 clinical data from the first cohort…
OraSure updated Its Emergency Use Authorization application for lab-based oral SARS-CoV-2 antibody test
On Dec. 21, 2020, OraSure Technologies disclosed that the FDA had requested additional information as part of its…
INOVIO to develop DNA-encoded monoclonal antibody (dMAb) candidates to treat COVID-19
On Dec. 15, 2020, Inovio Pharma announced the company and a team of scientists from The Wistar Institute,…
INOVIO dosed first subject in phase 2 segment of INNOVATE phase 2/3 trial for INO-4800 to prevent COVID-19
On Dec. 7, 2020, Inovio Pharmaceuticals announced it had dosed its first subject in a Phase 2 clinical…
INOVIO expanded global manufacturing consortium for COVID-19 vaccine candidate with Kaneka Eurogentec
On Dec. 3, 2020, Inovio Pharmaceuticals announced the execution of an agreement with Kaneka Eurogentec an affiliate of…
INOVIO announced initiation of phase 2/3 clinical trial for COVID-19 DNA vaccine candidate, INO-4800
On Nov. 16, 2020, INOVIO announced that it had received clearance from the the U.S. Food & Drug…
White-tailed deer found to be huge reservoir of SARS-CoV-2 infection
On Nov. 8, 2020, research from the U.S. had shown that white-tailed deer were being infected with SARS-CoV-2,…
OraSure’s DNA Genotek subsidiary received FDA EUA for its ORAcollect-RNA saliva collectiondevice for SARS CoV-2
On Nov. 3, 2020, OraSure Technologies announced its DNA Genotek subsidiary has received Emergency Use Authorization from the…
Data from Corvus phase 1 study of CPI-006 continued to support its potential as treatment for COVID-19
On Oct. 5, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
Hydroxychloroquine showed no benefit in COVID-19 prevention
On Sept. 30, 2020, researchers from the Perelman School of Medicine at the University of Pennsylvania reported results…
Biotechnology | COVID-19 | FDA | Infectious Disease | Life Science News | NIH | Vaccine
INOVIO reported FDA partial clinical hold for planned phase 2/3 trial of COVID-19 vaccine candidate INO-4800
On Sept. 28, 2020, INOVIO announced the U.S. Food and Drug Administration (FDA) had notified the company that…
INOVIO added Thermo Fisher Scientific to global manufacturing consortium
On Sept. 8, 2020, INOVIO announced that Thermo Fisher Scientific, the world leader in serving science, had signed…
RedHill Biopharma’s Opaganib awarded COVID-19 grant by State of Pennsylvania
On Sept. 3, 2020, RedHill Biopharma announced the selection of opaganib, a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2)…